Association between tumor size kinetics and survival in urothelial carcinoma patients treated with atezolizumab: implication for patient's follow‐up

Abstract : We characterized the association between tumor size kinetics and survival in advanced urothelial cancer patients treated with atezolizumab (anti-programmed death-ligand 1 (PD-L1), Tecentriq) using a joint model. The model, developed on data from 309 patients of a phase 2 clinical trial, identified the time-to-tumor growth and the instantaneous changes in tumor size as the best on-treatment predictors of survival. On the validation dataset containing data from 457 patients from a phase 3 study, the model predicted individual survival probability using 3 or 6-months tumor size follow-up data with an area under the receptor-occupancy curve between 0.75 and 0.84 as compared to values comprised between 0.62 and 0.75 when the model included only information available at treatment initiation. Including tumor size kinetics in a relevant statistical framework improve the prediction of survival probability during immunotherapy treatment, and may be useful to identify most-at-risk patients in "real-time". This article is protected by copyright. All rights reserved.
Liste complète des métadonnées

Littérature citée [52 références]  Voir  Masquer  Télécharger

https://www.hal.inserm.fr/inserm-02103513
Contributeur : Coralie Tardivon <>
Soumis le : jeudi 18 avril 2019 - 14:21:56
Dernière modification le : jeudi 9 mai 2019 - 15:58:01

Fichier

 Accès restreint
Fichier visible le : jamais

Connectez-vous pour demander l'accès au fichier

Identifiants

Citation

Coralie Tardivon, Solène Desmée, Marion Kerioui, René Bruno, Benjamin Wu, et al.. Association between tumor size kinetics and survival in urothelial carcinoma patients treated with atezolizumab: implication for patient's follow‐up. Clinical Pharmacology and Therapeutics, American Society for Clinical Pharmacology and Therapeutics, In press, Epub ahead of print. ⟨10.1002/cpt.1450⟩. ⟨inserm-02103513⟩

Partager

Métriques

Consultations de la notice

148